1. Home
  2. NUVL vs KNX Comparison

NUVL vs KNX Comparison

Compare NUVL & KNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$109.56

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo Knight-Swift Transportation Holdings Inc.

KNX

Knight-Swift Transportation Holdings Inc.

HOLD

Current Price

$51.28

Market Cap

7.0B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
KNX
Founded
2017
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trucking Freight/Courier Services
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
7.0B
IPO Year
2021
1994

Fundamental Metrics

Financial Performance
Metric
NUVL
KNX
Price
$109.56
$51.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
17
Target Price
$134.29
$53.65
AVG Volume (30 Days)
756.3K
2.9M
Earning Date
10-30-2025
01-21-2026
Dividend Yield
N/A
1.40%
EPS Growth
N/A
280.63
EPS
N/A
0.88
Revenue
N/A
$7,477,640,000.00
Revenue This Year
N/A
$2.37
Revenue Next Year
N/A
$5.55
P/E Ratio
N/A
$58.45
Revenue Growth
N/A
N/A
52 Week Low
$55.54
$36.69
52 Week High
$112.88
$61.51

Technical Indicators

Market Signals
Indicator
NUVL
KNX
Relative Strength Index (RSI) 62.75 73.47
Support Level $103.51 $45.64
Resistance Level $112.11 $44.72
Average True Range (ATR) 5.16 1.48
MACD -0.24 0.83
Stochastic Oscillator 83.81 94.09

Price Performance

Historical Comparison
NUVL
KNX

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About KNX Knight-Swift Transportation Holdings Inc.

Knight-Swift is the largest full-truckload carrier in the US, with a diversified transportation offering. Pro forma for the US Xpress deal, about 82% of revenue derives from Knight's asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 69% and less than truckload 13%. Truck brokerage and other asset-light logistics services make up 9% of revenue, with intermodal near 6%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue reflects services offered to shippers and third-party truckers, including equipment maintenance and leasing.

Share on Social Networks: